Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)

This study has been completed.

First Received: September 5, 2007 Last Updated: April 9, 2009 History of Changes

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00526552

Purpose

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes

Condition
Dyslipidemia Diabetes

MedlinePlus related topics: Diabetes

Drug Information available for: Rosuvastatin calcium Rosuvastatin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)

Further study details as provided by AstraZeneca:

Estimated Enrollment:	5000
Study Start Date:	June 2007
Study Completion Date:	December 2007
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria
1. Over 18 years of age
2. Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Exclusion Criteria:

Patients already taking other hyperlipidemic agents
Patients who do not fulfil the indication criteria for statin therapy
Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00526552

Locations

Korea, Republic of, Jongro-gu
Research Site
Seoul, Jongro-gu, Korea, Republic of
Korea, Republic of, Kangnam-gu
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Korea, Republic of, Songpa-gu
Research Site
Seoul, Songpa-gu, Korea, Republic of

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Hyunah Caroline Choi

AstraZeneca Korea

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	NIS-CKR-CRE-2007/3
Study First Received:	September 5, 2007
Last Updated:	April 9, 2009
ClinicalTrials.gov Identifier:	NCT00526552 History of Changes
Health Authority:	Korea: Food and Drug Administration

Keywords provided by AstraZeneca:

dyslipidemia
rosuvastatin
diabetes

cholesterol
Naturalistic
Observational

Study placed in the following topic categories:

Antimetabolites
Metabolic Diseases
Antilipemic Agents
Diabetes Mellitus
Endocrine System Diseases
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Rosuvastatin
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:

Antimetabolites
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Antilipemic Agents
Diabetes Mellitus
Endocrine System Diseases
Enzyme Inhibitors
Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions
Rosuvastatin
Therapeutic Uses
Glucose Metabolism Disorders
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on May 07, 2009